BioLineRx doses first patient in BL-8040 Phase I trial for stem cell mobilisation

Israel-based biopharmaceutical firm BioLineRx has dosed first patient in a two-part Phase I trial for a second indication of its BL-8040 cancer therapy platform, as a new stem cell mobilisation treatment.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusion Several TISC-based immunotherapeutic approaches are under development in various stages of preclinical studies. As outlined in this review article, a careful and more exhaustive genetic and metabolic understanding of TISC-associated phenotypes is critical to develop novel TISC based immunotherapies. Various components within the tumor microenvironment such as tumor cells, infiltrating immune cells, and supporting stromal cells impact the TISC metabolism. This unique metabolic profile leads to upregulation of certain enzymes and proteins such as ALDH1, CEP55, IDO COA1 etc., which can be utilized for development ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: 23 April 2019Source: Cell Reports, Volume 27, Issue 4Author(s): Erin E. Mulkearns-Hubert, Luke A. Torre-Healy, Daniel J. Silver, Jennifer T. Eurich, Defne Bayik, Emily Serbinowski, Masahiro Hitomi, John Zhou, Bartlomiej Przychodzen, Renliang Zhang, Samuel A. Sprowls, James S. Hale, Tyler J. Alban, Artem Berezovsky, Brent A. Bell, Paul R. Lockman, Babal K. Jha, Justin D. LathiaSummaryGap-junction-mediated cell-cell communication enables tumor cells to synchronize complex processes. We previously found that glioblastoma cancer stem cells (CSCs) express higher levels of the gap junction protein Cx46 compared...
Source: Cell Reports - Category: Cytology Source Type: research
In conclusion, we showed hypermethylation of CpGs as a novel mechanism of action for DNMTi agents and identified 638 hypermethylated molecular targets (CpGs) common to decitabine and azacytidine therapy. These novel results suggest that hypermethylation of CpGs should be considered when predicting the DNMTi responses and side effects in cancer patients. Introduction DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating the genome, with an aim to understand the role of DNA methylation in multiple processes (e.g., X-chromosome inactivation and DNA imprinting) and as an anti-ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 19 April 2019Source: Seminars in Cancer BiologyAuthor(s): Lingzhi Li, Zhuoyu Bi, Priya Wadgaonkar, Yongju Lu, Qian Zhang, Yao Fu, Chitra Thakur, Li Wang, Fei ChenAbstractAt present, the belief that genetic mutations control every aspect of tumorigenesis is still very popular. Even for the highly debated “bad luck” theory of cancers, it ascertained that random mutation of genes during the self-renewal of somatic stem cells is responsible for cancer initiation. Logically, most of the new therapeutic strategies so far, from molecular targeting to precision medicine or personalize...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
A microfluidic single ‐cell assay for screening therapeutic agents specific to cancer stem cells provides new tools for individualized cancer therapy. AbstractScreens of cancer stem cells (CSCs) ‐specific agents present significant challenges to conventional cell assays due to the difficulty in preparing CSCs ready for drug testing. To overcome this limitation, developed is a microfluidic single‐cell assay for screening breast cancer stem cell–specific agents. This assay takes advanta ge of the single‐cell clone‐forming capability of CSCs, which can be specifically inhibited by CSC‐targeting agents. The s...
Source: Small - Category: Nanotechnology Authors: Tags: Full Paper Source Type: research
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, CAR-T treatment combined with intratumoral delivery of poly I:C resulted in synergistic antitumor activity. We thus provide a rationale to translate this immunotherapeutic strategy to solid tumors. Introduction Adoptive T cell immunotherapy has been demonstrated to be a new way to fight malignancies. In particular, T lymphocytes engineered to express chimeric antigen receptor (CAR) have shown great promise in treating hematological malignancies (1). CD19-targeted CAR-T cells have been approved by FDA to treat relapsed B cell acute lymphoblastic leukemia (B-ALL) and Diffuse Large B-cell lymphoma (DLBC...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Oral mucositis is a significant complication of cancer therapy because of the associated pain and negative effects on the ability to eat, drink, and swallow and on the quality of life. Furthermore, oral mucositis increases the risk of systemic infection, and may interrupt cancer therapy. Oral mucositis manifests as erosions or ulcerations of the nonkeratinized oral mucosa, and its course depends on the form of cancer therapy. Oral mucositis affects an estimated 14% to 81% of patients undergoing some forms of chemotherapy, begins within days of initiating treatment, and lasts for up to 2 weeks depending on the dose, intensi...
Source: JAMA - Category: General Medicine Source Type: research
Lei Liu1,2,3, Lin Zhang1,2, Shuo Zhao4, Xu-Yang Zhao1,2, Peng-Xiang Min4, Ya-Dong Ma4, Yue-Yuan Wang4, Yan Chen1,2, Si-Jie Tang4, Yu-Jie Zhang2,4, Jun Du2,4 and Luo Gu2,4* 1Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, China 2Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China 3Department of Physiology, Xuzhou Medical University, Xuzhou, China 4Department of Physiology, Nanjing Medical University, Nanjing, China Tumor cell migration is a critical step...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusions In the new era of targeted therapy, treatment options are increasingly based on the precise molecular and genetic profiling of tumor cells (58). Currently, the main challenge for further novel drug development in targeted therapy is the clarification of specific molecular mechanisms underlying the varied forms of tumors in clinic. It has been acknowledged that cancer is caused by a set of driver mutations. In this regard, it is of great significance to: (1) identify and validate key mutant genes and proteins in cancers as new targets; (2) identify patients most likely and unlikely to benefit from certain targe...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Middle East Health | Pharmaceuticals | Stem Cell Therapy | Stem Cells